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According to current Global Initiative for Asthma (GINA)
guidelines, the recommended treatment option in patients with
mild to moderate asthma that remains uncontrolled with low-
dose inhaled corticosteroids (ICS) is to add a long-acting b2-
agonist (LABA) such as formoterol or salmeterol, before
increasing the ICS dose.1 Other controller options are the
addition of a leukotriene receptor antagonist or low-dose
theophylline.1 However, some patients do not respond to these
agents, whereas a substantial proportion of patients continue to
have symptomatic disease despite currently available therapies.2-4
Therefore, in patients with mild to moderate, uncontrolled
asthma, there is an unmet need for alternative therapeutic op-
tions. In such a population of patients, there is value in the
option to prescribe an agent with an alternative mechanism of
action to LABAs, such as a long-acting anticholinergic, for
example, because the side effects associated with LABA therapy
may be unacceptable in patients with mild disease.
Tiotropium is a once-daily long-acting anticholinergic bron-
chodilator indicated as maintenance treatment to relieve the
symptoms of patients with chronic obstructive pulmonary disease.
Phase II and phase III trials evaluated tiotropium delivered via the
Respimat Soft Mist inhaler (hereinafter also referred to as tio-
tropium Respimat; Boehringer Ingelheim Pharma GmbH & Co.
KG, Ingelheim am Rhein, Germany) in patients with symptom-
atic asthma despite maintenance treatment with medium-dose ICS
or high-dose ICS plus a LABA.5-8 In these studies, tiotropium
Respimat improved lung function and reduced exacerbation risk.5-
8
Another investigation studied tiotropium HandiHaler (Boeh-
ringer Ingelheim) in 210 patients with inadequately controlled
asthma while receiving low-dose ICS: the addition of tiotropiumHandiHaler was superior to doubling the dose of ICS with regard
to improvements in lung function and asthma symptoms.9 Here,
we report the ﬁrst clinical trial of tiotropium Respimat as add-on in
patients with not fully controlled, mild to moderate asthma despite
low- to medium-dose ICS maintenance therapy. In this phase III,
12-week study, the lung function efﬁcacy and safety of tiotropium
(5 mg or 2.5 mg) were evaluated compared with those of placebo.
METHODS
Study design
The efﬁcacy and safety of once-daily tiotropium Respimat 5 mg
or 2.5 mg add-on to low- to medium-dose ICS maintenance
therapy were compared with those of placebo Respimat in a
phase III, international, placebo-controlled, parallel-group study
(NCT01316380). Eligible patients completed a 4-week screening
period before randomization and entry into a 12-week, double-blind
treatment period with a 21-day follow-up period.
The trial was carried out in compliance with the principles of the
Declaration of Helsinki and the International Conference on Har-
monisation for Good Clinical Practice Guidelines. Before initiation,
the trial protocol, patient information sheet, and consent form were
reviewed and approved by each participating institution’s review
board. Before participation in the trial, written, informed consent
was received from each patient.
Study population
Eligible patients were aged 18-75 years, had a pre-bronchodilator
forced expiratory volume in 1 second (FEV1) 60% and 90% of
predicted normal at screening, had a history of asthma of 3 months
or more at study enrollment with initial diagnosis before the age of
40 years, and were symptomatic at screening and randomization
(deﬁned by mean 7-question Asthma Control Questionnaire
[ACQ-7] total score of 1.5). Patients had never smoked, or were
ex-smokers with less than 10 pack-years who stopped smoking at
least 1 year before enrollment.
Asthma was conﬁrmed at screening (FEV1 reversibility of 12%
and 200 mL 15-30 minutes after 400 mg salbutamol [albuterol])
and was mild and symptomatic despite current maintenance with
low- to medium-dose ICS (200-400 mg budesonide or equivalent
dose), that is, asthma was uncontrolled at GINA step 2,1 for 4 weeks
or more before screening.
Key exclusion criteria included a diagnosis of chronic obstructive
pulmonary disease, serious coexisting illness, concurrent use of
anticholinergic bronchodilators, and LABA therapy within 4 weeks
before enrollment.
Randomization and treatment
Patients were randomized 1:1:1 in blocks of 6 to either tio-
tropium 5 mg, tiotropium 2.5 mg, or placebo, all administered via the
Respimat Soft Mist inhaler once daily in the evening as add-on to
low- to medium-dose ICS maintenance treatment. They were
required to stop taking short-acting b2-agonists at least 8 hours
before visit 1 and continued to take their usual ICS asthma medi-
cation throughout the study. Randomization was achieved using a
validated, pseudo-random number generator and a supplied seed
number in a manner that was reproducible and nonpredictable. Each
patient inhaled 2 puffs from the Respimat Soft Mist inhaler once
daily in the evening. Medication was dispensed in a double-blind
fashion; the 2 different doses of tiotropium and placebo were
identical in appearance. Salbutamol (metered-dose inhaler; 100 mg
per puff) was dispensed as rescue medication.
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The primary efﬁcacy endpoint was peak FEV1 within 3 hours of
dosing (peak FEV1(0-3h)) response, where response was deﬁned as the
change from baseline at week 12. Peak FEV1(0-3h) was deﬁned as the
maximum value of the FEV1 measurements within 3 hours after
evening dosing. FEV1 measurements were performed 10 minutes
before study drug administration (baseline), and at 30 minutes,
1 hour, 2 hours, and 3 hours after dosing.
Secondary endpoints included trough FEV1 (key secondary
endpoint) and FEV1 area under the curve(0-3h) (AUC(0-3h)) responses
determined by the change in each parameter from baseline at week
12. Trough FEV1 was deﬁned as FEV1 measured at the end of the
dosing interval (24 hours after administration) and 10 minutes
before administration of the trial medication. FEV1 AUC(0-3h) was
calculated using the trapezoidal rule, divided by the observation time
(3 hours) to report in liters; trough values were assigned to time 0.
Use of salbutamol rescue medication was analyzed as the number
of puffs of rescue medication used during the daytime and night-
time and per day (ie, the full 24-hour period) on a weekly basis
during the 12-week treatment period and during the last 7 days
before visit 5 at week 12, and was recorded as a weekly mean
response from baseline. ACQ-7 total score at week 12 and morning
and evening pre-bronchodilator mean peak expiratory ﬂow (PEFAM
and PEFPM) responses (change from baseline at week 12) were also
assessed. Post hoc subgroup analyses of responses by gender, smoking
history, and baseline FEV1 % of predicted normal were performed.
All efﬁcacy evaluations were conducted at baseline and subse-
quently at week 4, week 8, week 12 (double-blind treatment period),
and week 15 (follow-up visit). Baseline and visits at weeks 4-12 were
conducted in the evening. Baseline was deﬁned as the respective
pretreatment value measured at the randomization visit, 10 minutes
before administration of the ﬁrst dose of trial medication.
At the time of screening, 12-lead electrocardiogram, physical
examination, and laboratory tests were performed. The safety and
tolerability of tiotropium Respimat were determined by the inci-
dence and intensity of adverse events (AEs) and changes in vital signs
measured at baseline (randomization visit) and at weeks 12 and 15.
AEs were monitored throughout the study.
Statistical analyses
The efﬁcacy and safety analyses were performed on the treated set,
deﬁned as all randomized patients who received at least 1 documented
dose of trial drug. The full analysis set was identical to the treated set.
The primary objective of the trial was to demonstrate the supe-
riority of tiotropium Respimat over placebo as add-on to low- to
medium-dose ICS maintenance therapy after 12 weeks of treatment.
The null hypotheses were tested in a stepwise manner to control the
probability of a type I error. First, the null hypothesis that mean
peak FEV1(0-3h) response at week 12 in the group receiving tio-
tropium Respimat 5 mg is not higher than in the group receiving
placebo was tested. If this hypothesis was rejected, then a similar null
hypothesis for the tiotropium Respimat 2.5 mg dose versus placebo
was tested. The second hypothesis was to be considered conﬁrmatory
only if the previous null hypothesis could not be rejected; that is, if
the superiority of treatment with tiotropium Respimat 5 mg over
placebo could not be established, analysis of the second hypothesis
was considered to be descriptive only.
The primary endpoint, peak FEV1(0-3h) response, was analyzed
using restricted maximum likelihood-based mixed-effects model
repeated measures. The model included the ﬁxed, categorical effects
of “treatment,” “center (pooled),” “visit,” and “treatment-by-visitinteraction,” as well as the continuous, ﬁxed covariates of “baseline
value” and “baseline value-by-visit-interaction.” The “center
(pooled)” variable represents the fact that centers and, if necessary,
countries with fewer than 5 treated patients were pooled until the
pool contained 6 or more patients. “Patient” was included as a
random effect in the model. An autoregressive (order 1) (co)variance
structure for equally spaced visits was used to model the within-
patient errors in the primary analysis. Signiﬁcance tests were based
on least-squares means using a 2-sided a ¼ 0.05 (2-sided 95%
conﬁdence intervals).
All continuous secondary endpoints were analyzed using restricted
maximum likelihood-based mixed-effects model repeated measures as
described above for the primary endpoint, unless stated otherwise.
Adjusted mean values as well as treatment contrasts were calculated,
together with the 95% conﬁdence intervals. All calculated P values
were to serve an exploratory function. No adjustment for multiplicity
was done, and all analyses were evaluated using a ¼ 0.05.
Sample size. Sample-size calculations determined that 150 pa-
tients per treatment group were required. Using a 2-sided test with a
type I error of 0.05 (ie, a) and assuming an observed standard de-
viation of 370 mL, this trial had a power of approximately 80% to
detect a difference of 120 mL between treatments in the change
from baseline of peak FEV1.
RESULTS
Between April 2011 and April 2012, 686 patients were enrolled
at 65 trial sites in 12 countries (Argentina, Austria, Croatia,
Estonia, Guatemala, Hungary, India, Italy, Korea, Latvia, Poland,
and Slovakia). Of these, 465 patients were randomized to receive
either tiotropium 5 mg (n¼ 155), tiotropium 2.5 mg (n¼ 154), or
placebo (n ¼ 156) (Figure 1). The discontinuation rate was low
(1.9%), and 464 patients were treated.
Overall, baseline patient demographics were generally
balanced across the treatment groups, with a few exceptions
(Table I). The mean age of the overall study population was 42.9
years. The median duration of asthma in each treatment group
was 15.0 years (range, 4.0 months to 61.0 years). No patients
currently smoked, and 17.7% were ex-smokers, although the
latter proportion was higher in the tiotropium 5 mg group.
Although the overall majority of patients were female, there
was a higher proportion of males in the tiotropium 2.5 mg group
compared with the 5 mg and placebo groups. Baseline charac-
teristics by gender are shown in Table E1 (available in this
article’s Online Repository at www.jaci-inpractice.org).
Efficacy
Primary endpoint. Both doses of tiotropium were superior to
placebo with regard to the primary endpoint of peak FEV1(0-3h)
response at week 12 (adjusted mean difference from placebo:
5 mg, 128 mL, P < .001; 2.5 mg, 159 mL, P < .001) (Table II;
Figure 2).
Secondary endpoints. Both doses of tiotropium were also
superior to placebo after 12 weeks with regard to the key
secondary endpoint of adjusted mean trough FEV1 response
(adjusted mean difference from placebo: 5 mg, 122 mL, P¼ .001;
2.5 mg, 110 mL, P ¼ .003) (Table II).
For other endpoints, both doses of tiotropium signiﬁcantly
improved FEV1 AUC(0-3h), PEFAM, and PEFPM responses
(Table II).
TABLE I. Baseline patient demographics and disease characteristics
Tiotropium 5 mg (n [ 155) Tiotropium 2.5 mg (n [ 154) Placebo (n [ 155) Total (N [ 464)
Age (y)* 41.9  13.0 43.8  14.0 42.8  12.1 42.9  13.0
Gender, n (%)
Male 59 (38.1) 72 (46.8) 52 (33.5) 183 (39.4)
Female 96 (61.9) 82 (53.2) 103 (66.5) 281 (60.6)
Body mass index (kg/m2)* 26.8  5.0 26.2  5.6 26.3  5.1 26.4  5.2
Smoking status, n (%)
Never smoked 122 (78.7) 131 (85.1) 129 (83.2) 382 (82.3)
Ex-smoker 33 (21.3) 23 (14.9) 26 (16.8) 82 (17.7)
Smoking history (pack-years)* 4.4  2.9 4.2  3.3 5.5  2.7 4.7  3.0
Median (range) duration of asthma (y) 15.0 (0.5-49.0) 15.0 (0.3-61.0) 15.0 (0.3-57.0) 15.0 (0.3-61.0)
FEV1 at screening*
Actual (L) 2.3 (0.6) 2.3 (0.7) 2.2 (0.6) 2.3 (0.6)
% of predicted 74.9 (8.1) 73.2 (8.6) 73.7 (8.5) 73.9 (8.4)
FEV1 at baseline (randomization)*
Actual (L) 2.5 (0.7) 2.4 (0.8) 2.4 (0.7) 2.4 (0.7)
% of predicted 79.6 (11.3) 75.8 (12.3) 77.5 (12.0) 77.7 (11.9)
FVC*
Actual (L) 3.6 (0.9) 3.6 (1.0) 3.5 (0.9) 3.5 (0.9)
% of predicted 97.4 (13.8) 95.6 (15.4) 96.7 (14.3) 96.6 (14.5)
FEV1/FVC at baseline (randomization) (%)* 69.7 (10.1) 67.4 (10.9) 68.5 (10.5) 68.5 (10.5)
PEFAM (L/min)* 363.1 (116.5) 350.5 (112.7) 353.7 (114.8) 355.8 (114.5)
PEFPM (L/min)* 377.5 (118.2) 364.1 (110.0) 363.7 (116.7) 369.8 (114.9)
ACQ-7 total score* 2.1 (0.4) 2.1 (0.4) 2.1 (0.4) 2.1 (0.4)
ICS dose of stable maintenance treatment (mg)*,† 376.9 (59.7) 384.4 (93.4) 383.0 (77.1) 381.4 (77.8)
ACQ-7, 7-question Asthma Control Questionnaire; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroids; PEFAM, morning peak
expiratory ﬂow; PEFPM, evening peak expiratory ﬂow.
Common baseline mean (standard deviation), weekly number of puffs of rescue medication: 1.841 (2.059).
*Values are mean  standard deviation.
†Budesonide or equivalent dose.
155 patients were assigned to
tiotropium 5 μg
154 patients were assigned to
tiotropium 2.5 μg 
156 patients were assigned to
placebo
465 patients underwent randomization
221 patients were not entered/not randomized
686 patients were assessed for eligibility
155 patients received
tiotropium 5 μg
154 patients received
tiotropium 2.5 μg
155 received patients
placebo
155 patients were analyzed for primary endpoint 154 patients were analyzed for primary endpoint 155 patients were analyzed for primary endpoint
152 patients completed the study
3 patients discontinued the study:
1 had an AE (not worsening asthma)
0 had lack of efficacy
1 had non-compliance
0 were lost to follow-up
0 withdrew consent (not due to an AE)
1 had other reasons
149 patients completed the study
5 patients discontinued the study:
2 had AEs (2 had worsening asthma)
0 had lack of efficacy
0 had non-compliance
0 were lost to follow-up
2 withdrew consent (not due to an AE)
1 had other reasons
154 patients completed the study
1 patient discontinued the study:
0 had AEs
0 had lack of efficacy
0 had non-compliance
0 were lost to follow-up
1 withdrew consent (not due to an AE)
0 had other reasons
FIGURE 1. Patient disposition. AE, adverse event.
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score were observed across all treatment groups after 12 weeks;
however, the differences between each dose of tiotropium versus
placebo were not statistically signiﬁcant (Table II).The adjusted weekly mean number of puffs of rescue medica-
tion used per 24 hours decreased during the trial in all treatment
groups (at week 12, the responses were tiotropium 5 mg, 0.848;
tiotropium 2.5 mg, 0.594; placebo, 0.815). However, the
TABLE II. FEV1, PEFAM, and PEFPM responses, and ACQ-7 total score, at week 12
Treatment and parameter Adjusted* mean (SE)
Active vs placebo
Adjusted* mean of difference (SE) (mL) 95% CI P value†
FEV1 responsez
Peak FEV1(0-3h) (mL) (primary endpoint)
Tiotropium 5 mg (n ¼ 152) 262 (26) 128 (36) 57, 199 <.001
Tiotropium 2.5 mg (n ¼ 151) 293 (26) 159 (36) 88, 230 <.001
Placebo (n ¼ 154) 134 (26)
Trough FEV1 (mL)
Tiotropium 5 mg (n ¼ 152) 137 (27) 122 (37) 49, 194 .001
Tiotropium 2.5 mg (n ¼ 151) 125 (26) 110 (37) 38, 182 .003
Placebo (n ¼ 154) 15 (26)
FEV1 AUC(0-3h) (mL)
Tiotropium 5 mg (n ¼ 152) 174 (25) 125 (34) 58, 192 <.001
Tiotropium 2.5 mg (n ¼ 151) 198 (24) 149 (34) 82, 216 <.001
Placebo (n ¼ 154) 48 (24)
Peak FEV1(0-3h) % predicted
Tiotropium 5 mg (n ¼ 152) 9.0 (0.8) 4.7 (1.1) 2.5, 6.8 <.001
Tiotropium 2.5 mg (n ¼ 151) 8.5 (0.8) 4.2 (1.1) 2.0, 6.4 <.001
Placebo (n ¼ 154) 4.3 (0.8)
Trough FEV1 % predicted
Tiotropium 5 mg (n ¼ 152) 4.8 (0.8) 4.4 (1.2) 2.1, 6.7 <.001
Tiotropium 2.5 mg (n ¼ 151) 3.0 (0.8) 2.6 (1.2) 0.3, 4.9 .02
Placebo (n ¼ 154) 0.4 (0.8)
PEFAM response (L/min)z
Tiotropium 5 mg (n ¼ 152) 23.0 (3.9) 25.6 (5.4) 14.9, 36.2 <.001
Tiotropium 2.5 mg (n ¼ 150) 23.7 (3.9) 26.3 (5.4) 15.7, 36.9 <.001
Placebo (n ¼ 152) 2.5 (3.9)
PEFPM response (L/min)z
Tiotropium 5 mg (n ¼ 152) 21.4 (3.8) 27.6 (5.3) 17.2, 38.0 <.001
Tiotropium 2.5 mg (n ¼ 149) 16.2 (3.8) 22.4 (5.3) 12.0, 32.8 <.001
Placebo (n ¼ 153) 6.2 (3.8)
ACQ-7 total scorex
Tiotropium 5 mg (n ¼ 152) 1.391 (0.049) 0.014 (0.067) 0.118, 0.146 .83
Tiotropium 2.5 mg (n ¼ 149) 1.438 (0.049) 0.061 (0.067) 0.071, 0.194 .36
Placebo (n ¼ 154) 1.377 (0.048)
ACQ-7, 7-question Asthma Control Questionnaire; AUC, area under the curve; CI, conﬁdence interval; FEV1, forced expiratory volume in 1 second; peak FEV1(0-3h), peak
forced expiratory volume in 1 second within 3 hours of dosing; PEFAM, morning peak expiratory ﬂow; PEFPM, evening peak expiratory ﬂow; SE, standard error.
Common baseline mean (standard deviation), mL, at visit 2: FEV1, 2420 (711); trough FEV1, 2422 (712). Common baseline mean ACQ-7 total score (standard deviation),
2.101 (0.415).
*Adjusted for treatment, center, visit, baseline, treatment-by-visit interaction, and baseline-by-visit interaction.
†Versus placebo.
zDifference between each parameter at 12 weeks and the baseline (measured 10 minutes before the ﬁrst dose of trial medication at randomization).
xACQ-7 total score is an absolute value; lower ACQ-7 score represents better control of asthma symptoms.
J ALLERGY CLIN IMMUNOL PRACT
JANUARY/FEBRUARY 2016
108 PAGGIARO ETALadjusted mean difference from placebo in weekly mean number of
puffs of rescue medication used per 24 hours was not signiﬁcant
for both tiotropium 5 mg (P ¼ .80) and tiotropium 2.5 mg
(P ¼ .09) at week 12. Weekly puffs of rescue medication in the
2.5 mg dose group tended to be higher compared with placebo
during the latter weeks of the trial and were signiﬁcantly higher
than placebo at night-time at weeks 8-11 (P ¼ .03 to .045; data
not shown) and at week 8 for 24-hour use (P ¼ .03; Table E2,
available in this article’s Online Repository at www.jaci-inpractice.
org), but there was no monotonic trend over time.
Signiﬁcant differences were observed in adjusted weekly mean
PEFAM and PEFPM for tiotropium 5 mg and 2.5 mg versus pla-
cebo at each week (Table II; Figure 3). There was a dose-ordering
pattern for PEFPM, a pre-bronchodilator measurement thatrepresents a true 24-hour value, with tiotropium 5 mg demon-
strating higher PEF values than 2.5 mg.
Post hoc efficacy analyses. Post hoc subgroup analyses of
peak FEV1(0-3h) and trough FEV1 responses were performed by
gender, smoking history, and baseline airway obstruction (FEV1
% of predicted normal). Tiotropium improved adjusted mean
lung function parameter responses from baseline to week 12 for
both genders, nonsmokers, ex-smokers, and those with a baseline
FEV1 of 60% to <80% or 80% of predicted normal post-
bronchodilator (Table III).
The absolute differences from placebo in peak FEV1(0-3h) and
trough FEV1 responses associated with tiotropium (both doses)
were greater in male patients than in female patients. Tiotropium
Pe
ak
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 (m
L)
Day 1 Week 4 Week 8 Week 12
500
450
400
350
300
250
200
150
100
50
0
Placebo (n = 154)
Tiotropium 5 μg (n = 152)
Tiotropium 2.5 μg (n = 151)
**
***
*
* *
*
FIGURE 2. Adjusted mean peak FEV1(0-3h) response over the 12-
week study period. *P < .05; **P < .001. Response defined as a
difference from the baseline value at randomization. Error bars are
 standard error. Baseline mean (standard deviation) FEV1, mL, at
visit 2: 2420 (711). Adjusted for treatment, center, visit, baseline,
treatment-by-visit interaction, and baseline-by-visit interaction.
FEV1, forced expiratory volume in 1 second; peak FEV1(0-3h), peak
forced expiratory volume in 1 second within 3 hours of dosing.
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trough FEV1 responses versus placebo in those who had never
smoked. Similar numerical differences were observed in ex-
smokers but were not statistically signiﬁcant, probably due to
the small number of ex-smokers analyzed (Table III). In patients
with baseline FEV1 60% to <80% of predicted normal post-
bronchodilator, statistically signiﬁcant peak FEV1(0-3h) and
trough FEV1 responses versus placebo were observed with the
tiotropium 5 mg dose, but not with the 2.5 mg dose. In the
80% of predicted subgroup, statistically signiﬁcant responses
versus placebo were observed with both tiotropium doses.
Safety and tolerability
The percentage of patients reporting AEs was similar across
the treatment groups (Table IV). The most frequently reported
events included asthma worsening (tiotropium 5 mg, 11.0%;
tiotropium 2.5 mg, 15.6%; placebo, 12.9%), decreased PEF rate
(tiotropium 5 mg, 3.9%; tiotropium 2.5 mg, 5.8%; placebo,
3.9%), and upper respiratory tract infection (tiotropium 5 mg,
4.5%; tiotropium 2.5 mg, 1.3%; placebo, 4.5%).
Most AEs were mild or moderate in intensity (Table IV). Two
patients (1.3%) in each treatment group were reported with AEs
that were considered to be drug-related by the investigator:
headache and dysphonia in the tiotropium 5 mg group, asthma
and hematuria in the tiotropium 2.5 mg group, and dry mouth
and hematuria in the placebo group.
AEs leading to discontinuation and serious AEs were infre-
quently reported. The serious AE (breast cancer in situ) for the
patient in the tiotropium 5 mg group required hospitalization;
the serious AE (severe asthma exacerbation) for the patient
receiving placebo was reported as an immediately life-threatening
serious AE and required prolonged hospitalization. Neither
serious AE was considered to be related to the study drug. There
were no deaths during this trial.
DISCUSSION
In this ﬁrst study of the efﬁcacy and safety of tiotropium
Respimat in patients with symptomatic mild to moderate asthma(uncontrolled at GINA step 21), a signiﬁcant improvement in
lung function was observed with tiotropium (5 and 2.5 mg)
compared with placebo after a 12-week treatment period. Both
doses of tiotropium achieved the primary endpoint of superiority
in peak FEV1(0-3h) response versus placebo, and also signiﬁcantly
improved trough FEV1, FEV1 AUC(0-3h), PEFAM, and PEFPM
responses.
The study enrolled patients with inadequately controlled
asthma at GINA step 2; these patients would thus be candidates
for treatment with a LABA, such as salmeterol or formoterol,
added on to low- to medium-dose ICS.1 Evidence from previous
active-comparator trials has indicated that tiotropium add-on to
at least ICS is comparable with add-on salmeterol for improving
lung function in patients with symptomatic asthma.5,9,10 The
current study has demonstrated that tiotropium also improves
lung function parameters in patients with not fully controlled,
mild to moderate asthma, when added on to low- to medium-
dose ICS. Furthermore, the airﬂow improvements seen here
with tiotropium appear to be of at least the same magnitude as
the addition of salmeterol or formoterol observed in other
studies,11-13 which suggests that tiotropium may have potential
as an alternative to LABA when added on to ICS of different
dose levels. Further investigation of tiotropium as an alternative
to LABA may be informative in this population, because the
current study did not include a LABA treatment arm.
A considerable improvement in lung function parameters was
observed in all treatment arms of this study between screening
and randomization; for example, FEV1 % predicted improved
from 74.9% to 79.6% in the tiotropium 5 mg group, from
73.2% to 75.8% in the tiotropium 2.5 mg group, and from
73.7% to 77.5% in the placebo group. This suggests that pa-
tients may have been ICS-naïve or noncompliant to ICS therapy
before baseline, and improvements in lung function in the
treatment period may reﬂect greater adherence to ICS treatment
during that period. This fact may explain the apparent modest
bronchodilation conferred by tiotropium (from randomization to
the end of the 12-week treatment period) compared with the
acute bronchodilation observed with salbutamol at the screening
visit.
Differences in treatment effect size between the 2 tiotropium
doses investigated were small; the trial was not powered to
demonstrate any statistical differences between the 2 doses of
tiotropium. The trend towards numerically greater responses for
some spirometry endpoints, particularly peak FEV1(0-3h)
response, with the 2.5 mg dose compared with the 5 mg dose was
further investigated and may be explained by baseline imbalances
in gender in each group. A higher proportion of male patients
was randomized to the 2.5 mg dose group than to the 5 mg dose
group and placebo group. Men tend to be taller than women,
and height correlates with lung volume, which may, in part,
explain the observed differences in response. The expected dose
ordering was observed in the 60% to <80% of predicted normal
post-bronchodilator subgroup, a measure that takes into account
differences related to the patient’s gender. With regard to PEF
response, a dose-ordering pattern was observed for PEFPM, with
tiotropium 5 mg demonstrating higher PEFPM values than the
2.5 mg dose. In this study, the PEFPM assessment measured the
24-hour bronchodilatory effect of tiotropium, because the drug
was administered in the evening. The beneﬁts of the 5 mg dose
have been widely reported in other studies, including 3 ran-
domized trials that demonstrated that tiotropium Respimat 5 mg
AB
FIGURE 3. Adjusted meanweekly morning PEF (A) and adjusted meanweekly evening PEF (pre-bronchodilator) (B). P <.05 vs placebo for
both tiotropium doses at all time points. Response defined as a difference from the baseline value at randomization. Error bars are 
standard error. Baseline mean (standard deviation) PEF, L/min, at visit 2: morning, 355.8 (114.5); evening, 369.8 (115.0). PEF, peak
expiratory flow.
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110 PAGGIARO ETALadd-on to ICS signiﬁcantly improved lung function versus pla-
cebo in patients with symptomatic moderate to severe asthma,5-7
and was noninferior to salmeterol. In addition, a phase II dose-
ranging study in patients with moderate symptomatic asthma
indicated that tiotropium 5 mg produced better FEV1 and PEF
responses than tiotropium 2.5 mg or 1.25 mg.8 From our data,
tiotropium 5 mg and 2.5 mg may be equally efﬁcacious in mild to
moderate asthma. However, taking into account data from pre-
vious studies across a range of asthma severities, tiotropium 5 mg
can be considered the preferred dose for use as add-on to ICS
maintenance therapy to improve lung function in patients with
asthma that is not fully controlled.
Previous studies have highlighted smoking history and level of
airﬂow obstruction as factors that can impact on response to
treatment.14,15 Although the subgroup analyses presented here
were exploratory in nature and contained limited numbers of
patients per group, it is valuable to note that tiotropium appeared
to elicit responses in all patients regardless of gender, smoking
history, or baseline FEV1 % predicted of normal. Importantly,peak FEV1(0-3h) and trough FEV1 responses versus placebo in the
60% to <80% of predicted normal post-bronchodilator sub-
group were greater with tiotropium 5 mg than with 2.5 mg. In the
80% subgroup, these responses versus placebo were more
similar between the 2 doses, although they were numerically
greater with tiotropium 2.5 mg. However, it should be remem-
bered that there is limited room for improvement in this sub-
group, making dose discrimination particularly difﬁcult.
At baseline, the mean total ACQ-7 score was 2.1 in each
treatment group, which indicated that asthma was uncontrolled.
After 12 weeks of treatment, all treatment groups recorded an
improvement in asthma control (ie, a decrease in score); how-
ever, mean scores in each group still remained in the “partially
controlled asthma” range (between 0.75 and 1.5). Furthermore,
neither dose of tiotropium achieved a difference from placebo
that was considered to reach minimum clinical importance (0.5).
However, the decrease in ACQ-7 for the placebo group was
higher than expected (>0.7), in contrast to a systematic review
and meta-analysis that observed an estimated mean decrease in
TABLE III. Post hoc efficacy analyses at week 12 by gender, smoking history, and FEV1 % of predicted post-bronchodilator
Treatment and parameter Adjusted* mean (SE) (mL)
Active vs placebo
Adjusted* mean of difference (SE) (mL) 95% CI P value*
Gender
Peak FEV1(0-3h) response
Males
Tiotropium 5 mg (n ¼ 58) 312 (48) 188 (70) 51, 326 .007
Tiotropium 2.5 mg (n ¼ 71) 367 (43) 244 (67) 113, 375 <.001
Placebo (n ¼ 51) 123 (51)
Females
Tiotropium 5 mg (n ¼ 94) 247 (33) 97 (46) 7, 187 .04
Tiotropium 2.5 mg (n ¼ 80) 238 (36) 87 (48) 7, 182 .07
Placebo (n ¼ 103) 150 (32)
Trough FEV1 response
Males
Tiotropium 5 mg (n ¼ 58) 180 (48) 191 (71) 52, 330 .007
Tiotropium 2.5 mg (n ¼ 71) 183 (44) 195 (67) 62, 327 .004
Placebo (n ¼ 51) 11 (51)
Females
Tiotropium 5 mg (n ¼ 94) 134 (34) 89 (47) 4, 181 .06
Tiotropium 2.5 mg (n ¼ 80) 95 (37) 50 (49) 46, 147 .31
Placebo (n ¼ 103) 45 (32)
Smoking history
Peak FEV1(0-3h) response
Never smoked
Tiotropium 5 mg (n ¼ 120) 281 (32) 132 (44) 45, 219 .003
Tiotropium 2.5 mg (n ¼ 129) 308 (31) 159 (43) 74, 244 <.001
Placebo (n ¼ 128) 149 (31)
Ex-smoker
Tiotropium 5 mg (n ¼ 32) 244 (55) 152 (82) 10, 314 .07
Tiotropium 2.5 mg (n ¼ 22) 243 (66) 150 (90) 26, 327 .10
Placebo (n ¼ 26) 92 (61)
Trough FEV1 response
Never smoked
Tiotropium 5 mg (n ¼ 120) 162 (32) 122 (45) 35, 210 .006
Tiotropium 2.5 mg (n ¼ 129) 142 (31) 102 (43) 17, 188 .02
Placebo (n ¼ 128) 39 (31)
Ex-smoker
Tiotropium 5 mg (n ¼ 32) 116 (59) 163 (87) 10, 335 .06
Tiotropium 2.5 mg (n ¼ 22) 98 (71) 145 (95) 43, 334 .13
Placebo (n ¼ 26) 47 (64)
FEV1 % of predicted normal post-bronchodilator
Peak FEV1(0-3h) response
60% to <80%
Tiotropium 5 mg (n ¼ 25) 288 (64) 200 (90) 21, 379 .03
Tiotropium 2.5 mg (n ¼ 30) 230 (58) 142 (86) 28, 311 .10
Placebo (n ¼ 25) 88 (63)
80%
Tiotropium 5 mg (n ¼ 127) 269 (31) 119 (43) 34, 204 .006
Tiotropium 2.5 mg (n ¼ 121) 316 (31) 166 (44) 81, 252 <.001
Placebo (n ¼ 129) 150 (30)
Trough FEV1 response
60% to <80%
Tiotropium 5 mg (n ¼ 25) 213 (67) 275 (95) 86, 463 .005
Tiotropium 2.5 mg (n ¼ 30) 37 (61) 99 (90) 79, 278 .27
Placebo (n ¼ 25) 62 (67)
(continued)
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TABLE IV. Overall summary of adverse events
n (%)
Tiotropium 5 mg
(n [ 155)
Tiotropium 2.5 mg
(n [ 154)
Placebo
(n [ 155)
Total
(N [ 464)
Patients with any AE 50 (32.3) 48 (31.2) 45 (29.0) 143 (30.8)
Patients with severe AEs 2 (1.3) 1 (0.6) 2 (1.3) 5 (1.1)
Patients with serious AEs* 1 (0.6) 0 1 (0.6) 2 (0.4)
Breast cancer in situ 1 (0.6) 0 0 1 (0.2)
Life-threatening asthma exacerbation 0 0 1 (0.6) 1 (0.2)
Patients with investigator-deﬁned drug-related AEs 2 (1.3) 2 (1.3) 2 (1.3) 6 (1.3)
Patients with AEs leading to discontinuation of study medication 1 (0.6) 2 (1.3) 0 3 (0.6)
AE, Adverse event.
*A patient may be counted in more than 1 category.
TABLE III. (Continued)
Treatment and parameter Adjusted* mean (SE) (mL)
Active vs placebo
Adjusted* mean of difference (SE) (mL) 95% CI P value*
80%
Tiotropium 5 mg (n ¼ 127) 140 (31) 99 (43) 13, 184 .02
Tiotropium 2.5 mg (n ¼ 121) 162 (31) 121 (44) 35, 207 .006
Placebo (n ¼ 129) 42 (31)
CI, Conﬁdence interval; FEV1, forced expiratory volume in 1 second; peak FEV1(0-3h), peak forced expiratory volume in 1 second within 3 hours of dosing; SE, standard error.
*Versus placebo.
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112 PAGGIARO ETALACQ-7 of 0.494 in patients receiving ICS therapy.16 An addi-
tional, unplanned analysis showed that 6-question ACQ (inde-
pendent of clinician-assessed lung function) results were
comparable with those of ACQ-7 (data not shown). Improved
compliance to ICS as a result of being a trial participant may
have been sufﬁcient to improve asthma control in the placebo
group, in this population of patients with mild to moderate
asthma. Furthermore, the study was predominantly designed to
assess lung function over a relatively short term (12 weeks), and a
longer time frame would perhaps be needed to record any dif-
ferences in clinical outcomes that may exist in patients with such
mild disease.
The magnitude of reduction in adjusted weekly mean number
of puffs of rescue medication was similar with tiotropium 5 mg
and placebo; however, signiﬁcant improvements with tiotropium
versus placebo were not to be expected because of the patient
population (mild to moderate asthma) under investigation.
Therefore, we believe that the lack of signiﬁcant improvement in
symptoms, as well as in rescue medication use, should not detract
from the clinical relevance of the functional improvement
observed with tiotropium in this population of patients with
mild to moderate asthma.
The incidence of AEs was comparable across the treatment
groups, and serious AEs and AEs leading to discontinuation were
rare.
Although the short trial duration, the absence of an active
comparator, and lack of power to detect clinical symptomatic
beneﬁt may be perceived as limitations of this trial, these 3-month
data conﬁrm the bronchodilatory effect of tiotropium that has been
reported in other trials in patients with asthma that remains un-
controlled despite ICSmaintenance therapy.5-8 The fact that there
is no known pathophysiological difference between patients with
mild and moderate asthma, coupled with evidence thatimprovements in lung function translate into clinical beneﬁts,17
suggest that a different and appropriately powered study design
may have detected signiﬁcant symptomatic outcomes.
This phase III study was a well-controlled, well-conducted
clinical trial in a representative population of patients with milder
symptomatic asthma than has previously been investigated. The
trial was able to conﬁrm that tiotropium add-on therapy im-
proves overall lung function in this group of patients also, further
increasing current knowledge of this therapy in different asthma
populations receiving various ICS doses. A statistically signiﬁcant
improvement versus placebo in ACQ-7 was not observed over
this short study period. This study was not designed to evaluate
an effect of tiotropium on asthma exacerbations. However, evi-
dence that improved lung function and control in adults with
mild to moderate asthma correlates with reduced risk of future
exacerbations,18 and that low lung function is considered a
predictor of future risk of exacerbations,1 suggests that the
observed improvements in airﬂow could offer clinically relevant
beneﬁts to patients in this population.CONCLUSIONS
Tiotropium Respimat was an efﬁcacious bronchodilator when
added to low- to medium-dose ICS maintenance therapy in a
population of adult patients with not fully controlled, mild to
moderate asthma. Once-daily tiotropium add-on improved lung
function after 12 weeks of treatment compared with placebo. The
safety and tolerability of tiotropium add-on to ICS maintenance
therapy were comparable with those of placebo, and both tio-
tropium doses were well tolerated over 12 weeks of treatment. The
data presented here provide further evidence for tiotropium
Respimat as an efﬁcacious alternative bronchodilator therapywhen
added on to ICS in inadequately controlled asthma.
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TABLE E1. Baseline patient and disease characteristics by gender
Tiotropium 5 mg Tiotropium 2.5 mg Placebo Total
Male
(n [ 59)
Female
(n [ 96)
Male
(n [ 72)
Female
(n [ 82)
Male
(n [ 52)
Female
(n [ 103)
Male
(n [ 183)
Female
(n [ 281)
Baseline
FEV1*
% predicted
pre-bronchodilator
73.5  8.0 75.7  8.0 72.8  8.0 73.6  9.1 72.6  7.6 74.3  8.9 73.0  7.9 74.6  8.7
% predicted
post-bronchodilator
at screening†
91.2  11.2 94.5  13.4 90.1  10.4 92.3  14.8 89.7  11.8 92.3  10.9 90.4  11.0 93.0  13.0
Reversibility (L)† 0.667  0.296 0.499  0.259 0.647  0.292 0.483  0.277 0.648  0.355 0.492  0.251 0.654  0.311 0.492  0.261
Reversibility (%)† 24.4  10.6 25.0  14.7 24.1  10.1 25.8  17.7 23.8  11.5 25.0  13.2 24.1  10.6 25.2  15.1
Predose at baseline (L)z 2.985  0.647 2.172  0.483 2.837  0.716 2.019  0.599 2.867  0.653 2.129  0.553 2.893  0.676 2.112  0.546
Body mass index (kg/m2)* 26.5  5.2 27.0  4.9 25.0  4.6 27.3  6.1 26.9  5.7 26.0  4.8 26.0  5.2 26.7  5.2
FEV1, Forced expiratory volume in 1 second.
*Values are mean  standard deviation.
†Visit 1 (screening).
zVisit 2 (randomization).
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TABLE E2. Weekly mean number of puffs of rescue medication used per day (response values)
Time point Treatment Adjusted* mean (SE)
Active vs placebo
Adjusted* mean of difference (SE) 95% CI P value†
Week 1 Tiotropium 5 mg (n ¼ 155) 0.685 (0.092) 0.132 (0.129) 0.385, 0.121 .31
Tiotropium 2.5 mg (n ¼ 154) 0.550 (0.093) 0.003 (0.129) 0.250, 0.256 .98
Placebo (n ¼ 155) 0.553 (0.093)
Week 2 Tiotropium 5 mg (n ¼ 153) 0.535 (0.093) 0.008 (0.129) 0.261, 0.245 .95
Tiotropium 2.5 mg (n ¼ 154) 0.464 (0.093) 0.064 (0.129) 0.189, 0.317 .62
Placebo (n ¼ 155) 0.527 (0.093)
Week 3 Tiotropium 5 mg (n ¼ 152) 0.570 (0.093) 0.002 (0.129) 0.255, 0.252 .99
Tiotropium 2.5 mg (n ¼ 154) 0.506 (0.093) 0.062 (0.129) 0.191, 0.316 .63
Placebo (n ¼ 154) 0.568 (0.093)
Week 4 Tiotropium 5 mg (n ¼ 152) 0.707 (0.093) 0.125 (0.129) 0.379, 0.128 .33
Tiotropium 2.5 mg (n ¼ 153) 0.485 (0.093) 0.097 (0.129) 0.156, 0.350 .45
Placebo (n ¼ 153) 0.582 (0.093)
Week 5 Tiotropium 5 mg (n ¼ 153) 0.736 (0.093) 0.047 (0.129) 0.300, 0.206 .72
Tiotropium 2.5 mg (n ¼ 152) 0.613 (0.093) 0.077 (0.129) 0.177, 0.330 .55
Placebo (n ¼ 153) 0.689 (0.093)
Week 6 Tiotropium 5 mg (n ¼ 153) 0.736 (0.093) 0.007 (0.129) 0.260, 0.247 .96
Tiotropium 2.5 mg (n ¼ 151) 0.549 (0.093) 0.180 (0.129) 0.074, 0.434 .16
Placebo (n ¼ 154) 0.729 (0.093)
Week 7 Tiotropium 5 mg (n ¼ 152) 0.744 (0.093) 0.056 (0.129) 0.309, 0.198 .67
Tiotropium 2.5 mg (n ¼ 150) 0.536 (0.093) 0.152 (0.129) 0.102, 0.405 .24
Placebo (n ¼ 153) 0.688 (0.093)
Week 8 Tiotropium 5 mg (n ¼ 153) 0.773 (0.093) 0.010 (0.129) 0.264, 0.243 .94
Tiotropium 2.5 mg (n ¼ 152) 0.489 (0.093) 0.274 (0.129) 0.020, 0.527 .03
Placebo (n ¼ 154) 0.763 (0.093)
Week 9 Tiotropium 5 mg (n ¼ 151) 0.879 (0.093) 0.078 (0.129) 0.332, 0.176 .55
Tiotropium 2.5 mg (n ¼ 151) 0.633 (0.093) 0.168 (0.129) 0.086, 0.422 .19
Placebo (n ¼ 153) 0.801 (0.093)
Week 10 Tiotropium 5 mg (n ¼ 151) 0.819 (0.093) 0.032 (0.129) 0.285, 0.222 .81
Tiotropium 2.5 mg (n ¼ 150) 0.621 (0.093) 0.166 (0.129) 0.088, 0.420 .20
Placebo (n ¼ 154) 0.787 (0.093)
Week 11 Tiotropium 5 mg (n ¼ 152) 0.789 (0.093) 0.022 (0.129) 0.232, 0.276 .86
Tiotropium 2.5 mg (n ¼ 150) 0.640 (0.093) 0.171 (0.129) 0.083, 0.425 .19
Placebo (n ¼ 153) 0.811 (0.093)
Week 12 Tiotropium 5 mg (n ¼ 152) 0.848 (0.093) 0.033 (0.129) 0.287, 0.221 .80
Tiotropium 2.5 mg (n ¼ 150) 0.594 (0.093) 0.222 (0.129) 0.032, 0.476 .09
Placebo (n ¼ 153) 0.815 (0.093)
CI, Conﬁdence interval; SE, standard error.
Common baseline mean (standard deviation) number of puffs of rescue medication, at week 0: 1.841 (2.059).
*Adjusted for treatment, center, week, baseline, treatment-by-week interaction, and baseline-by-week interaction.
†Versus placebo.
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